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Abstract
Clinical
Introduction
The landscape of COVID-19 and related therapies is a fast 
changing area of research. It now seems timely to synthesise 
some emerging trends and speculate about key future 
directions in COVID-19 pharmacotherapy given that we are 
unlikely to have an effective vaccine in the near future.
After initial infection via the nose with SARS-CoV-2 the 
virus rapidly spreads to the lungs to cause severe hypoxic 
pneumonia. In some susceptible individuals this may 
be accompanied by an exaggerated adaptive immune 
response involving a cytokine cascade and associated 
hyperinfl ammatory syndrome,1 followed by the development 
of acute respiratory distress syndrome (ARDS), assisted 
ventilation and ultimately death. In many respects, the later 
stages of severe COVID-19 infection manifests as a multi-organ 
viral-induced type of autoimmune disease (Figure 1). This 
infl ammatory process may be accompanied by a pronounced 
intravascular coagulopathy with elevated D-dimers, which 
may further aggravate ventilation-perfusion mismatch and 
worsening hypoxaemia.2 Hence low molecular weight heparin 
has been proposed to prevent thromboembolism.
In the earlier stages of COVID-19 infection one might expect 
antiviral strategies to be more effective on the upstream 
disease pathway. In the later stages, once cytokine-related 
hyperinfl ammation sets in, strategies to selectively suppress 
the immune response on the downstream pathway are 
more cogent (Figure 2).1 Patients who fare worst tend to 
be elderly, males, Black or Asian, smokers, obese, those 
with comorbidities such as chronic lung disease, diabetes, 
chronic heart disease, hypertension, dementia, chronic 
kidney disease, as well as those with neoplasia and 
immunosuppression.3
Upstream strategies
Initial interest inevitably focussed on antiviral therapies to 
arrest replication of SARS-CoV-2 with the aim of lessening the 
burden of viral load. In a randomised controlled trial (RCT) of 
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Broadly speaking, pharmacological treatments for COVID-19 can be divided 
into those acting on upstream pathways early on in the disease process via 
suppression of viral replication or by inhibiting cell entry, and those acting 
on downstream pathways later on via selective attenuation of the adaptive 
immune cytokine-mediated in ammatory response. The antiviral drug 
remdesivir has been shown to shorten duration of disease while interferon 
beta-1b may speed up viral clearance. The results with hydroxychloroquine have thus far been 
rather disappointing. Trials with selective cytokine blockers including anti-interleukin-1 (anti-
IL-1) and anti-interleukin-6 (anti-IL-6), have shown some promise in more severe cases, with 
further con rmation being required from large-scale phase-3 randomised controlled trials. The 
likelihood is that combination therapy addressing both upstream and downstream pathways 
may be required to prevent progression of severe COVID-19 infection in susceptible older 
patients with comorbidities and we believe further studies are now warranted to speci cally 
target such at-risk groups who are more prone to worse outcomes.
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199 patients with severe COVID-19, the combination of oral 
lopinavir/ritonavir was no more effective than standard of 
care (SOC) for the primary endpoint (PEP) of time to clinical 
improvement.4 In mild to moderate COVID-19 triple antiviral 
therapy comprising interferon beta-1b, ribavirin with lopinavir/
ritonavir, but not dual therapy without interferon beta-1b, 
signifi cantly shortened the duration of nasopharyngeal viral 
shedding by fi ve days and alleviated symptoms compared to 
lopinavir/ritonavir alone.5
A RCT comparing intravenous (IV) remdesivir with placebo 
in 237 severe COVID-19 patients found no significant 
difference in the PEP of time to clinical improvement or 
in mortality, although the trial had only 58% power due to 
premature termination.6 Preliminary data from 397 patients 
with severe COVID-19 found that 5 or 10 days of treatment 
with IV remdesivir were equally effective, although no control 
group was included.7 Interim analysis of data from the 
National Institute of Allergy and Infectious Diseases in the 
USA comparing IV remdesivir to placebo in 1063 patients 
with severe COVID-19 revealed a signifi cantly shorter median 
Figure 1 Depicts the concept 
of multi-organ viral-induced 
autoimmune disease with 
severe COVID-19 associated 
cytokine-mediated 
hyperinflammation. ACE2: 
angiotensin converting 
enzyme-2, TMPRSS2: 
transmembrane protease 
serine 2 enzyme, NSP15: 
nonstructural protein 15, 
SARS-CoV-2: severe acute 
respiratory syndrome 
coronavirus-2
Figure 2 Depicts the potential 
upstream (suppression of viral 
replication and inhibition of cell 
entry) and downstream 
(selective anti-cytokine) 
pharmacological targets for 
COVID-19. IL: interleukin, TNF: 
tumour necrosis factor, JAK: 
Janus kinase, ACE2: 
angiotensin converting enzyme 
2, TMPRSS2: transmembrane 
protease serine 2 enzyme, 
NSP15: nonstructural protein 
15, SARS-CoV-2: severe acute 
respiratory syndrome 
coronavirus 2
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recovery time amounting to four days but no signifi cant 
difference in deaths at 14 days (7.1% vs 11.9%).8 On the 
basis of this result, the USA Food and Drug Administration 
granted authorisation for emergency use of remdesivir for 
severe COVID-19, and by the European Medicines Agency for 
compassionate use in patients not on mechanical ventilation. 
Azithromycin (AZI) also has putative antiviral activity, as well 
as downstream immune-modulating effects on cytokines and 
has been included in the UK National Institute of Health 
Research (NIHR) primary and secondary care trials.
Much publicity has surrounded the potential use of 
hydroxychloroquine (HCQ). It acts upstream by arresting 
endocytic host-cell entry of SARS-CoV-2 into type 2 
pneumonocytes, attaching via angiotensin-converting enzyme 
2 (ACE2). In addition, HCQ also has a downstream effect by 
inhibiting release of the proinfl ammatory cytokines including 
interleukin-6 (IL-6). One RCT in 36 hospitalised patients 
treated with HCQ reported a signifi cant reduction in viral 
load compared to controls.9 In an open label randomised 
trial of 150 mild to moderate COVID-19, use of HCQ led 
to a similar probability for the PEP of virus elimination 
compared to SOC.10 A comparative observational trial of 
HCQ in 181 hypoxic severe COVID-19 patients showed no 
signifi cant impact compared to SOC on the PEP of survival 
without transfer to intensive care on day 21, while 10 % of 
patients had HCQ stopped due to prolongation of the QTc 
interval.11 A pragmatic observational study of 1376 patients 
from New York City showed no signifi cant difference in the 
PEP of death or intubation after propensity score weighting, 
amounting to a 4% difference comparing patients who were 
taking to those not taking HCQ, although patients taking HCQ 
had worse oxygenation and higher CRP levels at baseline.12 
Furthermore, there was no significant association with 
concomitant use of AZI and the PEP. It should be appreciated 
that QTc prolongation with HCQ may be aggravated by co-
administration with AZI and therefore electrocardiogram 
monitoring should be performed when both drugs are given 
concomitantly.13 As it stands, the present evidence does not 
support use of HCQ in either early or late stage COVID-19.
Cell uptake of zinc may be augmented by combining with an 
ionophore such as HCQ. In 933 hospitalised patients the 
addition of zinc to HCQ/AZI resulted in signifi cantly improved 
outcomes as a 33% increased likelihood of patients being 
discharged from hospital and a 45% lower likelihood of need 
for intensive care or intubation.14
Much larger pragmatic RCTs have embraced HCQ including 
NIHR trials in primary care as monotherapy (PRINCIPLE) and 
in secondary care as either monotherapy or in combination 
with the anti-IL-6 agent tocilizumab (RECOVERY) or with 
antivirals (REMAP-CAP).
Blocking viral cell entry via transmembrane protease, serine 
2 enzyme (TMPRSS2)15 is another possibility, using the cough 
remedy bromhexine given alone or in combination with HCQ 
(NCT04340349, NCT04355026, NCT04273763). Notably, 
inhaled corticosteroids (ICS) have also been found to reduce 
gene expression of ACE2 and TMPRSS2 receptors in sputum 
cells of asthma patients, which might confer protection 
against progression of COVID-19 infection.16
Downstream strategies
Circulating maximal levels of IL-6 above 80 pg/ml are 
associated with a 22-fold increased risk of impending 
respiratory failure in severe COVID-19 patients, being indicative 
of hyperinfl ammatory syndrome.17 Another cohort reported 
that IL-6 above 32 pg/ml and CRP above 42 mg/l at initial 
presentation were indicative of worse clinical outcomes.18
Early attention has focussed on repurposing anti-IL-6 agents, 
namely tocilizumab and sarilumab which are indicated for 
rheumatoid disease. Uncontrolled data from compassionate 
use of tocilizumab as a single subcutaneous 400mg dose 
in 21 patients with severe COVID-19 showed improvements 
within fi ve days in fever, CRP, lymphocyte counts, imaging 
infiltrates and oxygenation, with 90% of cases being 
discharged within a mean period of 13.5 days after 
administration.19 An early analysis of preliminary phase-2 
RCT data in 457 hospitalised COVID-19 patients showed 
that IV sarilumab 200mg or 400mg compared to placebo 
signifi cantly lowered the PEP of CRP levels but had no overall 
clinical benefi t in combined severe or critical patient groups.20 
Post hoc exploratory analysis of the 400mg dose in critical 
patients showed a 23% absolute difference in patients who 
either died or were being ventilated, 18% difference for 
those who showed clinical improvement, 12% difference 
in patients able to wean off oxygen, and 29% difference in 
those who were discharged from hospital. Other placebo 
RCTs are evaluating tocilizumab alone or in combination 
with antivirals: RECOVERY, COVACTA (NCT04320615) and 
TOCOVID (NCT04322773 and NCT04310228).
Systemic cor t icosteroids exhibit  non-select ive 
immunosuppressive effects and thus far have shown no 
improvement in severe COVID-19 outcomes, perhaps in part 
due to the possibility of inducing secondary bacterial and fungal 
infections.21 However, recent interest has centered on using 
ICS as a potential strategy for earlier intervention. ICS exhibit 
protective class effects by attenuating viral cell-entry as well as 
inhibiting downstream IL-6.16,22 In addition, there is a specifi c 
ICS effect conferred by ciclesonide and mometasone, but not 
budesonide, beclomethasone or fl uticasone, via nonstructural 
protein 15 which results in attenuated replication of SARS-
CoV-2 in vitro.23 In South Korea, a study using ciclesonide 
will evaluate SARS-CoV-2 eradication in patients with mild 
COVID-19 infection (NCT04330586).
Other downstream selective immune modifi ers which are 
being investigated include anti-IL-1,anti-tumour necrosis factor 
and selective Janus kinase (JAK) inhibitors. An uncontrolled 
trial in 45 hospitalised COVID-19 patients with the anti-IL-1 
agent IV anakinra at high dose showed a signifi cant 34% 
difference in survival after 21 days when compared to a 
retrospective standard of care group, but no difference in 
mechanical ventilation-free survival.24
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Next Steps
It remains to be seen if either antivirals or blockers of viral cell 
entry can be used for effective secondary prevention in early-
stage infection to modify the severity of COVID-19. It is very 
unlikely that a single agent will prove to be the ‘magic bullet’ in 
later stage severe COVID-19. Hence combinations of upstream 
and downstream disease modulators may be required as 
either dual or triple therapy.1 Using biomarkers such as IL-6 
or CRP should help to identify hospitalised patients with 
hyperinfl ammatory syndrome at greater risk of respiratory 
failure who may need escalation of treatment. Future clinical 
trials should be focussed on preventing susceptible older 
patients with comorbidities from developing severe outcomes.
Key Messages
• Severe COVID-19 manifests as a viral-induced multisystem 
autoimmune disease characterised by an adaptive 
cytokine-mediated immune response with associated 
hyperinfl ammation and coagulopathy
• Elevated biomarkers such as IL-6 and CRP indicate 
worsening hyperinfl ammation and impending respiratory 
failure with a commensurate need to escalate therapy
• Combination therapy addressing upstream and 
downstream pathways, for example using antivirals with 
selective cytokine inhibitors, may be required to prevent 
progression of severe COVID-19 infection
• Randomised controlled trials need to be targeted at 
susceptible older individuals with comorbidities who tend 
to have worse outcomes associated with COVID-19 
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